EAN News

The Innovative Health Initiative (IHI) has just published draft topic texts for its upcoming Call 11, expected to launch officially in late June 2025.

The EAN was asked by a media outlet to provide comment on the possible role of creatine in the prevention of Alzheimer’s disease, the subject of much recent internet speculation.

Following an earlier decision by the EMA, the EU Commission has granted EU authorisation for Lecanemab to treat mild cognitive impairment in the early stages of Alzheimer’s disease.

We are immensely proud to announce that the 10th Congress of the European Academy of Neurology, held at the Messukeskus, Helsinki, in 2024, has been named Best Corporate Event Subject to a Fee at the 2024 Evento Awards, a Finnish event industry award that recognises the best events, venues, speakers, creators and companies in Finland.

Each month the eanNews editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for April 2025.

EAN Communications Committee Chair, Matilde Leonardi, looks back on an extremely busy and productive period of communication activity for the EAN.

Welcome to the April 2025 edition of the President’s Corner, our article series in which the EAN President, Elena Moro, answers your questions!

Our Paper of the Month is a prospective cohort study conducted in the US, including participants from the Nurses’ Health Study (NHS) and the Health Professionals Follow-Up Study (HPFS).

Watch a full recording of the latest European Brain Health Summit, held in Brussels on 19 March under the heading 'Brain Health for a Resilient Europe'.

Each month the eanNews editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for March 2025.

EAN Education Committee Chair, Nathalie Nasr, provides an update on the full range of EAN learning opportunities.

Welcome to the March 2025 edition of the President’s Corner, our article series in which the EAN President, Elena Moro, answers your questions!

Our paper of the month for March is a phase 3 multicentre, double-blind, randomised trial investigating whether treatment with exenatide can slow the progression of Parkinson’s disease.

We are pleased to announce two Joint Sessions co-hosted by the EAN at the 33rd European Congress of Psychiatry (Madrid, 5-8 April)

EAN Treasurer, Jana Midelfart-Hoff reviews her "fantastic experience" in office over the last six months, representing the EAN and the Brain Health Mission on various levels